Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.59 |
| ▸ | SYK | P43405 | 2/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 8/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917205 | 0.86 | KDR (0.56) | CDK1SYKPRKCQCNR2CTSC | |
| SCHEMBL1916571 | 0.85 | GSK3A (0.56) | CDK1SYKCTSCJAK2JAK3 | |
| SCHEMBL1916005 | 0.85 | PRKCQ (0.54) | CDK1SYKPRKCQCNR2CYP2C9 | |
| SCHEMBL2508768 | 0.83 | SYK (0.54) | CDK1SYKPRKCQCTSCJAK2 | |
| SCHEMBL1938235 | 0.83 | SYK (0.50) | CDK1SYKPRKCQCTSC | |
| SCHEMBL27850474 | 0.83 | ULK1 (0.60) | CDK1SYKCNR2CTSC | |
| SCHEMBL1935907 | 0.83 | SYK (0.47) | CDK1SYKPRKCQCNR2CTSC | |
| SCHEMBL1917337 | 0.82 | STK17A (0.60) | CDK1SYKMAOBGRM5CNR2 | |
| SCHEMBL1917193 | 0.82 | SYK (0.48) | CDK1SYKCTSC | |
| SCHEMBL1917507 | 0.82 | ULK1 (0.50) | CDK1SYKCNR2CTSCCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | disclosed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| EP-1663991-B1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PROD INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-7122670-B2 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1663991-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | Pfizer Products Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005023780-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PRODUCTS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | CDK1 39/4885SYK 2248/4885PRKCQ 3224/4885 |
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | HNRNPH3, HNRNPA3, NUDT1 | CDK1 541/4885SYK 4177/4885PRKCQ 4847/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | CDK1 17/4885SYK 918/4885PRKCQ 3897/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | CDK1 39/4885SYK 2248/4885PRKCQ 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.